Pharma Journalist

mRNA Process Development & Manufacturing Summit
2022-09-20 - 2022-09-22 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The mRNA Process Development & Manufacturing Summit will be taking place in-person in Boston, MA this month (September 20 – 22, 2022). The only conference roadmap to accelerate mRNA drug substance process scale up and manufacturing!
This conference will showcase the pioneering work of 30+ global leaders across 3 days of immersive content sharing new data, allowing you to stay ahead of the curve.
If you and your team are looking to learn how to overcome mRNA process scale up and manufacturing hurdles towards regulatory harmonization by optimizing in vitro transcription, purification, and analytical validation of your mRNA drug substance, then you should attend this dedicated industry forum to see the outlook to this advancing and dynamic field.
Multiple functions from 75+ leading companies and their teams have already registered, here’s just a snapchat:

Director – Business Development mRNA Therapeutics
Senior Director – Manufacturing Science & Technology
Head of Quality
Principal Applications Scientist – mRNA
Director – Formulation and Drug Delivery
Principal Scientist – Early Bioprocess
Senior Process Development Associate – mRNA
Group Leader (RNA Reagents) – Production
Downstream Scientist – Technical R&D
Scientist II – Analytical Development
Director – RNA Therapeutics Development R & D
Director – CMC RNA Vaccines Biopharmaceutical Development
Associate Director – Drug Substance
Senior Director – CMC Reg Affairs Regulatory

With very limited passes remaining, register today and be part of the conversation.
To know more visit: https://ter.li/9v5h9k

Pre-Filled Syringes San Francisco
2022-09-19 - 2022-09-20 | Hyatt Centric, Fisherman’s Wharf, San Francisco, CA, 94133, United States
SAE Media Group’s 3rd Annual Conference
September 19 – 20, 2022 | San Francisco, CA, USA
————————————————————————-
The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products.

This year’s conference will be assessing the latest developments in new technologies for next generation device design, including computational simulation approaches forming the digital revolution of devices design. Furthermore, the latest advances in digital combination product development will be explored through the lens of lifecycle management and user-centric combination products. Leading experts from big pharma will be presenting case studies on recent advances in platform approaches in drug delivery devices and smart devices, while a panel discussion will explore the emerging opportunities of platforms for injectable devices. With recent developments in industry regulations and guidance, the 2022 agenda will give an international insight into the global regulatory environment and leading FDA representatives will address the key standards to be aware of in injectable device development.
Over recent years we have seen the need for injectable devices to adapt to novel therapeutics. Our expert industry thought leaders will present case studies and updates to the industry’s approach to injectable delivery for novel drug products. Furthermore, our speakers will be assessing the key considerations for primary packaging and CMC approaches to injectable device development.
As part of SAE Media Group’s leading injectable drug delivery portfolio, this event is not to be missed.
The two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
To know more visit: http://www.prefilled-sanfrancisco.com/pharmajournalistwl

2nd Annual Aseptic Processing Conference
2022-09-19 - 2022-09-20 | London, UK
2nd Annual Aseptic Processing Conference
Conference: 19 – 20 September 2022
Workshop: 21 September 2022
London, UK
http://www.asepticprocessing.co.uk/PJWL

Sponsored by: Dec Group, Rapid Micro Biosystems, Raumedic and STERIS

Conference Chairman: James Drinkwater, Head of Aseptic Processing Special Interest Group PHSS and Head of GMP Compliance, F Ziel GMBH
Driving a Holistic Approach to Assurance of Product Sterility through Aseptic Manufacturing following QRM Principles
SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference, this year taking place in London, on the 19 and 20 September 2022.
The Aseptic processing industry has seen consistent growth in recent years, with advances in innovative therapeutics, the introduction of novel techniques and personnel protocols, the integration of robotics and automation in filling lines, and rise of rapid microbiological methods being just a few of the factors driving this growth.
The Aseptic Processing equipment market was approaching a valuation of 10 billion USD in 2015, and is projected to exceed 12 billion USD in value by next year, then to far surpass a total market value of 50 billion USD before the end of the decade.
Join us to discuss and address the Guidance and Regulation including the EU GMP Annex 1, environmental control delving into the contamination control strategy, Pharma moving forward 4.0 covering data integrity and data consistency, robotics in aseptic processing and exploring the continued aseptic processing development in Annex 1 and environmental monitoring
This event is CPD Accredited
Event Hashtag: #AsepticProcessing
Benefits of Attending:

Discuss the revisions and the impact of Annex 1 on aseptic manufacturing
Explore the applications of rapid micro methods in the manufacture of sterile products
Discover a risk-based approach to cleaning and disinfection
Delve into case studies of competence in global aseptic manufacturing
Uncover the journey of isolation technology in a large biotech pharmaceutical plant
Analyse the new abilities of robotics and automation through their integration into aseptic technique

Who Should Attend?

Validation Managers
Senior Microbiologists
Senior QA’s and QC’s
Quality Control Managers
Heads of GMP Compliance
Quality Assurance Experts
Technical Operations Leads
Leaders in Sterility Assurance
Cleanroom Managers
Regulatory Affairs Managers
Production Managers
Quality Systems Managers
Heads of Quality Compliance
Process Leaders
Senior Auditors
Bioprocess Research & Development

PLUS – Post-Conference Workshop on 21 September 2022…
Implementation Strategy of Annex 1 in New or Existing Facilities
Led by: Richard Denk, Senior Consultant Aseptic Processing & Containment, Skan AG
View the brochure and to download visit http://www.asepticprocessing.co.uk/PJWL

7th CAR-TCR Summit
2022-09-19 - 2022-09-23 | Boston, MA
Back to Boston with a bang! With 1,500 CAR and TCR developers, 200 speakers, 150 live presentations, 20 hours of networking and more surprises in store, the 7th CAR-TCR Summit will be the BIGGEST ever.
Gain end-to-end insights from industry giants and the innovators bringing disruptive technologies from bench to bedside and from vein to vein.
Discuss everything from novel allogeneic approaches with enhanced safety considerations, the latest in vivo gene engineering techniques, and advances in CMC and analytics to ensure the development of high-quality cell products.
With your industry reuniting in-person for the first time since 2019 to discuss leveraging the powerful potential of iPSC platforms, learnings from our successes and pitfalls, and manufacturing automation innovations for large scale consistent production, you can’t afford to miss the 7th Annual CAR-TCR Summit as we bring you more speakers, more content and more exclusive insights than ever before!
To know more visit: https://ter.li/km5zwy

5th Microbiome Movement – Skin Health & Dermatology Summit
2022-09-13 - 2022-09-15 | Four Points by Sheraton Boston Logan Airport Revere, 407 Squire Rd, Revere, MA, 02151, United States
Translating Scientific Methodologies Addressing the Skin Microbiome into Commercially Viable Dermatological Therapeutics & Cosmetic Products
Skin microbiome research is continuing to gain increasing market traction from a number of stakeholders, including drug developers and cosmetic brands. For investment and progress to continue, it is vital to meet and connect with the key opinion leaders in the space.
Now in its fifth year, the Microbiome Movement – Skin Health & Dermatology Summit will unite the field’s leaders from academia and industry to address the unique scientific and commercial challenges of working in the skin microbiome. This meeting will provide a platform for crucial discussions which will hasten the development of microbiome-targeting therapeutics and cosmetics that focus on characterization, clinical testing, and product commercialization.
This is your opportunity to connect with 100+ collaborative thought leaders in the skin microbiome field from academics, drug developers, cosmeceutical developers, cosmetic and consumer brands, to obtain a holistic view of the microbiome dermatology landscape that will revolutionise your product pipeline.
Find out more about the meeting, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/nzhrvy
Or become one of our event partners and showcase your company’s latest technologies and solutions! Get in touch with us directly or request a partnership prospectus here: https://ter.li/9kybuv
We look forward to welcoming you to Boston in September!

3rd Annual Gene Therapy for Ophthalmic Disorders
2022-09-13 - 2022-09-16 | Westin Boston Seaport, 425 Summer Street, Boston, MA, 02210, United States
Revolutionizing Genetic Therapy Development & Delivery to the Eye
Discovering Next Generation Administration Routes for the Eye; Overcoming the Translational Challenges of Ophthalmic Preclinical Models; & Discussing Toxicity & Targeting Challenges of Vector-Based Approaches
The ophthalmology field is bursting with novel genetic approaches for targeting many disorders, with gene therapy taking centre stage as a one-time treatment option. With more invasive subretinal approaches being used in the clinic, as well as more innovative outpatient methods such as suprachoroidal delivery, there are a lot of pros and cons to discuss as the field progresses towards developing efficacious and durable treatments for many ophthalmic disorders.
Returning for its 3rd year, the Gene Therapy for Ophthalmic Disorders is the definitive forum for those working on ophthalmic gene therapy. This is the only conference that unites pharma and biotech to address the most pressing challenges, with focus on discussing and sharing solutions with the key leaders in the industry.
This year we have expanded into two streams of learning, putting more emphasis on the individual challenges faced in both the preclinical and clinical phases of ophthalmic gene therapy drug development.
Gene therapy for ophthalmic disorders has only seen one FDA approved therapy, which drug will be the next? Join 150+ of your peers to discuss and overcome the barriers preventing drugs getting to market.
Leave the definitive 3rd Annual Gene Therapy for Ophthalmic Disorders forum equipped with knowledge of novel methods and developments, actionable lessons learned and new connections. Don’t miss your opportunity to be a part the conversation which could lead to the next drug approval.

5th International Cannabinoid-Derived Pharmaceuticals Summit
2022-09-06 - 2022-09-08 | Boston, MA (venue TBC)
Over the last half-decade, we have witnessed game-changing developments within the cannabinoid field, driving it into a new era of rigorous research, promising clinical trials and multimillion-dollar deals. Right now, there are 50 cannabinoid therapeutic trials taking place at phases 2 and 3, pushing for approval to meet the clinical needs of patients with chronic pain, cancer, psychiatric conditions and much more. Despite these positive changes and rapid industry growth there remains key challenges to overcome for drug developers regarding the human evidence gap, funding and changing regulation – to name just a few.
The 5th International Cannabinoid-Derived Pharmaceuticals Summit is uniting drug developers, investors, solution providers and academics from around the globe working to overcome these challenges and progress the field of cannabinoid therapeutics. 35+ expert speakers will lead sessions on critical topics across 3 days of presentations, panel discussions and interactive workshops in Boston.
Agenda highlights include:

Present a poster of your drug development pipeline at our investor networking session, and connect with the decision makers looking to fund promising cannabinoid therapeutics
Get the most up-to-date regulatory perspectives from the FDA and other organizations with Dominic Chiapperino (FDA) and Cassie Taylor
(FDA)
Produce and source high-purity cannabinoids from synthetic, plant-based and biosynthetic sources with Purisys, Kinetochem and our other world-leading partners
Hear from the key opinion leaders at the forefront of next-generation cannabinoid-derived pharmaceutical development including Alistair Vickery (Emyria), Brian Murphy (Former CEO of Emerald Bioscience) and Jeff Chen (Radicle Sciences)
Streamline successful late-stage clinical trials and be the next one across the finish line with a multi-format and highly interactive session with Sud Agarwal (Cannvalate)
Join 2 half-day workshops – one dedicated to bridging the gap between OTC and prescribed pharmaceuticals, and an additional behind-the-scenes workshop on the psychedelics field, preparing you for exploration into a new area
Connect with 80+ thought leaders and industry peers as they come together to drive discussion and progress across the 3-day event

The Summit focuses on the real science in the cannabinoid industry and is the only chance to connect with likeminded, analytical professionals looking to move the dial forward in this exciting space. Check out the event guide for the full agenda

Optimizing AAV Safety Summit
2022-09-06 - 2022-09-08 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Hundreds of clinical trials using AAV are underway, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline, the need to administer high doses, the clinical holds placed on gene therapy trials, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that’s fit for purpose!
In this setting, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology, pharmacology, non-clinical study leads, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays.
Join us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics, Ask Bio, Eli Lilly, Takeda, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies, learn how clinical safety signals have changed how companies are approaching their pipeline progression, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.
To know more visit: https://ter.li/r92wow

2nd Integrin-Targeted Drug Development Summit
2022-08-30 - 2022-09-01 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Over the last 12 months, the industry has witnessed promising data and candidates entering the clinic. 7 Hills Pharma, Corbus Pharmaceuticals, Vincerx, and Morphic are paving the way to develop a safe, efficacious integrins-targeted drug to modify disease biology, which will be a game-changer for diseases such as oncology, autoimmune, and ophthalmology, with unmet medical needs.
In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success, including patient selection biomarkers and dosing.
Get your critical questions answered to supercharge your clinical programs, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic, familiar, and rare diseases.
Join us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients.
To know more visit: https://ter.li/qoq74v

6th IPF Summit
2022-08-29 - 2022-09-01 | Westin Boston Seaport District, 425 Summer St, Boston, MA, 02210, United States
With two approved therapeutics and the field working to develop the next generation of IPF drugs, the opportunity to become the undisputed, most effective, and disease-modifying agent on the market has never been greater.
From repairing and regenerating lung tissue to illuminating innovative clinical trial design and advance scientific progress; the 6th IPF Summit is your one-stop-shop to supercharge IPF research and drug development.
What’s new and unmissable for 2022:

29 brand new industry speakers, as well as returning KOLs including Fernando Martinez, Naftali Kaminski, Toby Maher, and many more
6 interactive workshops to delve into IPF’s hottest topics, discuss challenges, pose your burning questions to leading experts, and highlight the respiratory pipeline development opportunities including SSc-ILD, COPD, and COVID fibrosis
A brand-new Tissue Repair and Regeneration Day, with dedicated sessions on halting and reversing disease progression to rethinking senescence to unlocking cell therapies. Get more insight than ever before on evolving basic science and regenerative therapy opportunities
Exclusive presentations on the regulatory and patient perspectives to inform clinical trial design and future therapeutic development

Get in the room with your team to meet peers and KOLs and take away critical insights at the world’s most comprehensive and dedicated IPF conference. Confirmed attendees include AbbVie, Boehringer Ingelheim, Bayer, BMS, Genentech, Galecto, Novartis, and Trevi Therapeutics.
From navigating pathophysiology and pathobiology, exploring all available target opportunities to leveraging synthetic control arms in clinical trials; this is a conversation you won’t want to miss to transform your IPF research.
To know more visit: https://ter.li/6yo2nd

Cell Therapy Analytical Development Summit Europe
2022-08-23 - 2022-08-25 | Hilton London Paddington, 146 Praed St, London, W2 1EE, United Kingdom
Cell Therapy Analytical Development Summit Europe, taking place from 23-25 of August in London, will bring together professionals working in CMC, QC, process development, and regulatory functions.
Join your peers in person to:

Learn to develop a successful potency assay to determine product activity
Explore reference standards for state-of-the-art analytical development
Discover new technology to expand and improve your analytical toolbox
Develop and validate analytical methods to fulfil GMP guidelines
Streamline final product characterisation by starting with the end in mind

You can view the event guide here: https://ter.li/nxuxfd
Secure your place at the summit here: https://ter.li/551w6c
We are looking forward to welcoming you to London this August!

Targeted Radiopharmaceuticals Summit US (TRP US)
2022-07-26 - 2022-07-28 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The brand-new Targeted Radiopharmaceuticals Summit US (TRP US) is the only industry-led meeting dedicated to developing next-generation radioligands. The TRP sector has developed dramatically over the previous 18 months, with a wave of new investment in light of Lutathera’s extraordinary performance.
Are you part of a pharmaceutical business aiming to have their Theranostic approved? If so, this agenda is designed to deliver you a well-rounded and complete understanding of the fast-paced radiopharmaceutical sector while also learning about the critical function of diagnostic imaging.
Hear the latest insights, case studies, and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies.
To know more visit: https://ter.li/jtzz4q

iPSC Manufacturing Summit
2022-07-26 - 2022-07-28 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
With iPSCs exhibiting game-changing potential in the bid to develop an off-the-shelf therapy, the brand-new iPSC Manufacturing Summit is the only summit dedicated to solving the manufacturing, quality and analytical challenges hindering your iPSC-derived treatments from reaching patients.
This forum will unite the exclusive community advancing the production of high-quality and consistent iPSC products, with in depth case studies aimed to develop optimal differentiation, cryopreservation, and analytical protocol to enhance process development to ensure it is robust, rapid and repeatable.
Our 17+ expert speakers will be addressing methods to enhance potency testing and cell characterization, enhance iPSC product quality, and integrate successful gene-editing into your manufacturing.
Take a look at the full event guide to learn more.

2nd Annual mRNA-Based Therapeutics Summit
2022-07-26 - 2022-07-28 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Do you want to be part of the largest gathering of mRNA professionals?
The 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28.
Expect exclusive data from the movers and shakers in mRNA vaccine and therapy development, 75+ world-class speakers, 5 dedicated tracks of content and 45+ deep-dive case studies. Find out more in the full event guide: https://ter.li/yc800m
Here’s a snapshot of the expert speakers you can hear from:

​​​​Kathy Fernando, VP, Head of Worldwide Research, Development and Medical Operations & Head of mRNA Scientific Planning, Pfizer
Regis Gervier, Global Head, mRNA Center of Excellence, Sanofi
Rituparna Das, VP – COVID Vaccines, Moderna
Hao Chen, Global Head of Cell & Viral Drug Substance, GlaxoSmithKline
Joe Payne, Founder, President & CEO, Arcturus Therapeutics
Pervin Anklesaria, Deputy Director, HIV Vaccines & Biologics, Bill & Melinda Gates Foundation
Manmohan Singh, SVP – Pharmaceutical Sciences & Delivery Technologies, Beam Therapeutics
Akhilesh Bhambhani, Senior Director – Biologics Drug Product Development; Tech Dev/Tech Ops, Ultragenyx
Liang Shang, Senior Scientist – Vaccine Analytical, Merck
Russell Johnson, VP – Formulation Research, RVAC Medicines
Tamar Grossman, Global Head – RNA & Targeted Therapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson

Download the official brochure to discover why Sanofi, Ultragenyx, Beam Therapeutics, Pfizer, Moderna, Merck, Eli Lilly, GSK, and 300+ others have already secured their places. https://ter.li/yc800m

Cytokine-Based Drug Development Summit
2022-07-26 - 2022-07-29 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
The 3rd Cytokine-Based Drug Development Summit has been developed following extensive research to address YOUR biggest challenges in the cytokine field.
With 30+ expert speakers, including the hottest academic researchers and leading figures from the industry, this 4-day program is your opportunity to gain insight into the latest clinical advancement and have thought provoking discussions around how to overcome the fields greatest drug development challenges.
What can you expect to see?

Further your understanding of the underlying mechanisms of action, and T-cell exclusion from the tumor in order to turn cold tumors ‘hot’ with Ask-Gene Pharma
Optimize cytokine engineering to ensure stability and improve the favorable risk benefit profile with Proviva Therapeutics
Leverage insights from industry’s leading lights to overcome toxicity challenges by ensuring tumor targeting is selective and therefore enhances the anti-tumor response with Equilium, Cytonus Therapeutics & Cytimmune
Take a deep dive into preclinical cancer models covering both in vitro and in-vivo studies and how these are unveiling the most favoured pharmaceuticals properties of therapeutic cytokines with Astra Zeneca & Xilio Therapeutics
Uncover the latest data coming out of the clinic of cytokines in combination with checkpoint inhibitors and monoclonal antibodies with Alkermes & NeoImmune Tech

Get your copy of the brand-new agenda for the full list of speakers and sessions.

3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit
2022-07-26 - 2022-07-28 | The Bostonian, 26 North St, Boston, MA, 02109, United States
The 3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit is the only industry-led forum focused on the therapeutic opportunity of drugs directed against B-cell, plasma cell, and T-cell targets in autoimmunity.

Several drug approvals for B-cell directed therapies have made waves in autoimmune drug development. As investment and industry momentum increases, this summit will once again unite the movers and shakers of the B&T cell-mediated autoimmune space with the likes of Pfizer, Nurix, Regeneron, Gossamer Bio, and more.
Take a look at the 2022 program here.
Attending this summit is a unique opportunity to be involved in interactive discussions on:

Overcoming challenges of heterogeneity of disease models and demonstrating B cell activation in tissues
Emerging therapies including B-cell specific therapies, tolerizing approaches, small molecule drugs, engineered cell immunotherapy, B&T cell checkpoint targeting, FcRn inhibition, as well as PROTAC/degrader approaches
Therapeutic opportunities across both peripheral and tissue specific autoimmune diseases
Overcoming clinical challenges of treating B&T cell mediated autoimmune diseases through combinatorial regimens that target T-cell co-stimulation, leveraging autoantibody signatures to identify patient responders and discussing autoimmune disease biomarkers

As the space grapples with translational and early clinical drug development challenges, join this comprehensive forum 80+ key leaders and decision-makers to harness the immune system and conquer B&T cell mediated autoimmune diseases.

3rd Gamma Delta T Therapies Summit
2022-07-26 - 2022-07-28 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The data has dropped and 2022 has been touted as a monumental year for γδT Therapies
With Adicet Bio, In8Bio, Gamma Delta Therapeutics, Lava Therapeutics, and ImCheck Therapeutics releasing clinical data from engineered and antibody-based γδT Therapy in patients; the race to market for the first allogeneic and solid tumor-targeting γδT Therapy is truly on.
Join the 3rd Gamma Delta T Therapies Summit to learn and network with 120+ of the world’s leaders including γδT pioneer, Adrian Hayday, and together accelerate the development of effective, persistent, globally accessible cell therapy for solid tumors.
Take a look at the official program here.
Enhance cytotoxicity, discover novel targets, engineer stealth and persistence, interrogate cell subsets, and scale-up manufacturing through a deep understanding of the fundamental biology and target product profile for γδT therapies.
Industry experts agree that this year, the γδT is the cell to know. Ensure you and your team are ahead of the curve and equipped with the need-to-know insights to advance successful therapeutics, across 2 dedicated tracks covering Discovery, Process Research, Preclinical, and Clinical Development; as well as 3 deep-dive workshops, and a Gamma Delta 101 Bootcamp.

Cell Therapy Potency Assay Summit
2022-07-25 - 2022-07-27 | The Bostonion, 26 North Street, Boston, MA, 02109, United States
Cell Therapy Potency Assay Summit, taking place from 25-27 of July in Boston, will bring together professionals working in analytical development, quality, regulatory and process development functions.
Join your peers to:

Brainstorm best-in-class approaches to overcome variability in QC
Compare next gen approaches from cytotoxicity to omics
Develop reference standards to benchmark across the industry
Create an assay with commercialization in mind.

This summit will equip you with the tools you need to fast track your regulatory submissions and ease through clinical development.
You can view the event guide here: https://ter.li/6a13vg
Secure your place at the summit here: https://ter.li/zp17ep
We are looking forward to welcoming you to Boston this July!

LEAP HR Life Sciences East
2022-07-18 - 2022-07-20 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
LEAP HR: Life Sciences East 2022 Conference will be taking place as an in-person event in Boston, July 18-20. Returning as a physical event for its seventh year, this event will showcase 35+ case studies of how life sciences organizations of all stages and sizes are redefining post-pandemic best practices and turbocharging the employee experience to meet the holistic and previously unmet needs of your in-demand life science workforce.
This is a unique chance to take advantage of a combination of plenary sessions, breakout sessions, panels and roundtable discussions specifically designed to solve your biggest HR challenges and deliver actionable insights for HR innovation.
Network with 250+ other strategic HR leaders working within life sciences on the East Coast and surrounding areas and join a support network of 500+ life science HR leaders who have previously taken part.
You’ll hear from companies such as: Takeda, Novo Nordisk, AstraZeneca, Pfizer, Alexion Pharmaceuticals, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, BioNTech, Ipsen, Novartis, PTC Therapeutics, TCR2 Therapeutics, Ginkgo BioWorks and more…
Find out more by visiting the website: https://leap-hr-lifesciences-east.com/

2nd Annual Next Generation Gene Therapy Vectors Summit
2022-07-18 - 2022-07-20 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
Overcome First Generation Gene Therapy Vector Challenges To Guarantee Targeted, Specific, Efficient & Safe Gene Delivery
The 2nd Next Generation Gene Therapy Vectors Summit is dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors to deliver safe and efficacious gene therapy products.
Industry pioneers from cutting edge biopharma and world-leading academic vectorology groups are set to share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely.
Spanning a range of delivery approaches from cutting-edge AAV capsid optimization, utilizing lenti and other viral vectors, to innovative non-viral gene therapy approaches, this comprehensive event will enable you to reduce immunogenicity, improve tissue targeting, simplify manufacturing and enhance the safety profile of your approach.
Everything in gene therapy starts with delivery, so join this definitive, niche conference to delve into the details of vector design, engineering and optimization case studies, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before.
To know more visit: https://ter.li/3mccj3

RNA Therapeutic Modalities Summit USA
2022-07-15 - 2022-07-16 | Boston, USA
The RNA Therapeutic Modalities Summit is North America’s only industry led conference covering clinical progress and commercial scale development for the full spectrum of RNA therapeutic approaches.
Our agenda will featuring the pioneering biotechs translating current vaccine success into further clinically validated treatments in broader indications using RNA technologies such as antisense oligonucleotides, aptamers, small interfering RNAs (siRNAs), microRNAs, and messenger RNA (mRNA).
There will be dedicated discussion on the rationale for different mechanisms-of-action, how to optimise the power and versatility of RNA-based constructs, and the progress to date in disease indications encompassing neurodegeneration, metabolic and cardiovascular disorders and various cancers.
If your R&D teams are looking to establish a differentiated drug platform through RNA modification and delivery systems, improve stability, delivery and durability of current drug candidates, or enable tissue-specific administration with higher targeting ability and less toxicity, make sure they secure a place at this hotly anticipated conference. We look forward to welcoming you to Boston for dedicated in-person networking in June!
To know more visit: https://hubs.ly/Q012R75G0

Advanced Wound Care Summit
2022-07-13 - 2022-07-14 | Boston, MA (Venue TBD)
The Advanced Wound Care Innovation Summit is the first industry-led forum focused on delivering innovative wound care treatments to patients. Expect to hear from, and discuss with, world leaders of wound care research who are driving the development of novel biomaterials, remote-monitoring devices, and digital health management solutions.
Find out how C-level Executives, VPs and Directors of R&D are tackling the most pressing industry challenges and seizing new growth opportunities. Whether an executive, investor, researcher or healthcare professional, this meeting offers an empowering environment that allows you to make wound care decisions with confidence.
To know more visit: www.advancedwoundcareusa.com

BCMA Targeted Therapies Summit
2022-07-12 - 2022-07-14 | The Bostonian, 26 North St, Boston, MA, 02109, United States
With the undeniable excitement in the BCMA field over the past few months, the BCMA-Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize your BCMA-centered pipeline.
Pick the brains of 90+ academic and industry pioneers at the first physical edition of the only meeting dedicated to supercharging transformative next generation BCMA-targeted therapies into the clinic, navigating the complex landscape and optimizing clinical strategy to revolutionize treatment of multiple myeloma and beyond.
Hear from leading speakers including:

Suzette Girgis, Senior Director & Head of Clinical Pharmacology & Hematologic Malignancies, Johnson & Johnson Services
Eric Fedyk, Global Program Leader of BCMA Assets, 2seventy bio
David DiLillo, Director, Immuno-Oncology, Regeneron
Brandon Kremer, Group Senior Medical Director, Clinical Development Lead, GlaxoSmithKline
Nathan Martin, Translational Scientist & Project Lead, Bristol Myers Squibb
Mike Damore, Director & Lead – Translational Oncology, Pfizer
Chetasi Talati, Medical Director, AbbVie
Dexiu Bu, Senior Principle Scientist, CART group, Immuno-Oncology & Hematology, Novartis
Faiza Zafar, Senior Medical Science Liaison, Legend Biotech

Take a look at the full event guide to learn more.

3rd GxP Cloud Compliance Summit
2022-07-12 - 2022-07-14 | The Bostonian, 26 North St, Boston, MA, 02109, United States
Migrate Your GxP Regulated Applications to the Cloud with Compliance, Security, & Quality Assurance
With hot anticipation for the FDA’s new CSA guidance, life science companies have the opportunity to take a proactive stance in their approach to the new methodologies. In the climate of this exciting new era of computer systems validation, join over 100 Life Science, IT & Quality professionals at the 3rd GxP Cloud Compliance Summit.
Emulating on 2021’s success, the 3rd GxP Cloud Compliance Summit is excited to return in July, for the first time in person!
This is your only opportunity to develop and implement a practical roadmap to migrate your GxP regulated applications to the cloud with real-life insights from regulatory, security and quality experts from leading life science companies, as well as cloud providers, auditors, and industry regulators.
With the FDA strongly advising life science organizations to start getting ready for CSA now, join us in July to discover how your business can get ahead and simplify the transition process.
To know more visit: https://ter.li/uichgz

Digital Biomarkers and Clinical Measures in Neurology Summit
2022-07-11 - 2022-07-13 | The Bostonian, 26 North St, Boston, MA, 02109, United States
The Digital Biomarkers & Clinical Measures in Neurology Summit is the definitive industry forum sharing cross-industry insight to transform clinical development with digital data.
From integrating wearable technologies, smartphone apps, and speech-based digital biomarkers into remote clinical research to elucidating pathways to clinical validation to establish therapeutic efficacy, join industry experts from Merck, Janssen, GSK, Sanofi, Novartis, Takeda, Eli Lilly & Company, Mitsubishi Tanabe Pharma Holdings America and many more to improve patient retention and establish efficacy with richer datasets.
To know more visit: https://ter.li/mk4lmh

3rd Annual Gene Therapy for Neurological Disorders Europe
2022-07-11 - 2022-07-13 | Paris Marriott Charles de Gaulle Airport Hotel, Zone Hoteliere, 5 All. du Verger, Roissy-en-France, 95700
Accelerating Europe’s Progress in CNS Gene Therapy
Navigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic
As programs advance globally, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the industry’s definitive forum dedicated to showcasing the European landscape’s progress and specific regulatory challenges as they move from rare neurological disorders to targeting more common diseases including Parkinson’s, epilepsy and neurodevelopmental disorders.
Returning as its first in-person meeting, with brand new speakers and companies joining the conversation, attend alongside 100 fellow preclinical, translational, clinical and commercial gene therapy experts to overcome your translational challenges and improve the delivery of your gene therapy to its CNS target, and optimize your European strategy as you move from rare to common patient populations.
To know more visit: https://ter.li/l4b1t3

Microbiome Connect: Europe
2022-07-06 - 2022-07-07 | Amsterdam
The 8th Annual Microbiome Connect: Europe 2022 dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers.
As the first EMA approved microbiome-targeted therapeutics emerge on the horizon, drug developers will have to opportunity to benchmark their rational drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications.
Furthermore, there will be separate tracks dedicated to developing novel, clinical-validated product formulations for nutritional, digestive wellness, oral and skincare applications.
Join the microbiome field to hear from biotechs, pharma voices, investment bodies, consumer product brands and more, on how to develop robust, scalable, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market.
To know more visit: https://hubs.ly/Q012R7H40

11th Annual HPAPI Summit
2022-06-28 - 2022-06-30 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
Undoubtedly, the past two years have changed the pharma industry forever; new modalities are dominating pharma pipelines, drugs are increasing in potency, and the restrictions around product quality are tighter than ever before.
It is integral that the HPAPI community comes together to apply expertise in ensuring operator safety, alongside product quality, to the future of hazardous drug production and fully understand this new landscape, and regulatory environment. Built in collaboration with industry experts, the HPAPI Summit provides end-to end coverage tackling; development, commercial manufacturing & tech transfer, occupational toxicology, industrial hygiene & EHS, across small molecules, large molecules, drug conjugates & ATMP, for a holistic approach to bullet-proofing your hazardous drug production.
With sessions championed from the likes of Merck, Bayer, AstraZeneca, Takeda and more, don’t miss this opportunity to reconnect, reassess and re-enforce your risk management for your potent pipeline and production at the longest standing and largest global summit for highly potent API’s & hazardous drugs.
Save up to $700 on your event pass when you book before Friday, May 20.
Group discounts of up to 20% are also available when you bring your team!
To know more visit: https://ter.li/3csco9

3rd TCR-based Therapies for Solid Tumors Summit
2022-06-27 - 2022-06-29 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Are you using TCRs to target solid tumors yet?
With Immunocore having achieved commercialization for the first TCR therapy and Adaptimmune hot on their tail, 2022 is fast becoming the year for TCRs.
Join the TCR-based Therapies for Solid Tumors Summit (June 27-29) to gain knowledge to accelerate the clinical development and improve the safety of these game-changing cell therapies.
Featuring 24+ expert speakers, over 80% of whom are new for 2022, this summit will address the toughest challenges in TCR development, such as improving TCR discovery and efficacy, combating the tumor microenvironment, optimizing target selection and advancing manufacturing, preclinical and clinical processes.
Join leaders in the field, including Adaptimmune, Iovance and TScan as they examine methods to prevent cross reactivity, increase cell fitness and infiltration, improve therapy safety and ultimately overcome the hurdles holding back these game-changing treatments from patients in need.
Find out more in the Event Guide: https://ter.li/sa0pnw

Non-Viral RNA Delivery Systems Summit
2022-06-21 - 2022-06-23 | The Bostonian, 26 North St, Boston, MA, 02109, United States
Built with biopharmaceutical industry insights, this in-person conference will delve into the latest advancements of non-viral RNA delivery systems such as LNPs, exosomes and polymers to set the scene for the translation of targeted, safe and durable delivery systems for RNA therapeutics and vaccines with improved formulation, distribution and tissue-specificity.
Don’t miss 20+ pioneering speakers from large pharma, innovative biotech, and KOLs of academia who are shaping the landscape of advanced and emerging non-viral RNA delivery systems for the RNA biopharma community worldwide.
Join this meeting to hear cutting-edge science and latest data on:

Expand Therapeutic Applications with Emerging Non-Viral RNA Delivery Systems
Discover Novel LNP & Alternative Technologies to Increase Specificity & Efficacy
Learn About the Latest Improvements of Non-Viral Delivery Systems for the Delivery of a Broad Range of RNA Payloads
Increase Tissue Specific & Extrahepatic Delivery through Optimizing Formulation & Design
Delve into the emerging Engineering, Formulation & Packaging Methods to Improve Non- Viral RNA Delivery & Stability

Join 80+ VPs, Heads and Directors of RNA delivery, Formulation and Process development for a deep dive into delivery challenges and strategies of non-viral systems to fully unleash the therapeutic opportunities offered by different RNA therapeutics and vaccines.
To know more visit: https://ter.li/ai0qwx
